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Abstract
Congenital cytomegalovirus (CMV) infection occurs in
0.6–0.7% of all newborns and is the most prevalent
infection-related cause of congenital neurological handi-
cap. Vertical transmission occurs in around 30% of cas-
es, but the fetus is not always affected. Symptomatic
newborns at birth have a much higher risk of suffering
severe neurological sequelae. Detection of specific IgG
and IgM and IgG avidity seem to be the most reliable
tests to identify a primary infection but interpretation in a
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clinical context may be difficult. If a seroconversion is
documented or a fetal infection is suspected by ultra-
sound markers, an amniocentesis should be performed
to confirm a vertical transmission. In the absence of a
confirmed fetal infection with fetal structural anomalies,
a pregnancy termination should be discouraged. Fetal
prognosis is mainly correlated to the presence of brain
damage. Despite promising results with the use of anti-
viral drugs and CMV hyperimmune globulin (HIG), results
have to be interpreted with caution. Pregnant women
should not be systematically tested for CMV during preg-
nancy. Managing CMV screening should be restricted to
pregnancies where a primary infection is suspected or
among women at high risk. The magnitude of congenital
CMV disease and the value of interventions to prevent
its transmission or to decrease the sequelae need to be
established before implementing public health interven-
tions. In this paper, aspects of CMV infection in the preg-
nant woman and her infant are reviewed.
Keywords: Amniotic fluid (AF); congenital cytomegalo-
virus (CMV); polymerase chain reaction (PCR).
Introduction
Human cytomegalovirus (CMV) is an opportunistic path-
ogen belonging to the herpesviridae family. Like other
viruses in this family, it shares properties of latency and
reactivation w18, 22, 78x. It is widely distributed and can
spread through close interpersonal contact with infected
body fluids, usually saliva, urine, blood or genital secre-
tions. It is an endemic infection without seasonal
variations.
In immunocompetent adults, primary infection is usu-
ally asymptomatic even during the acute stage. Fewer
than 5% of pregnant women with primary infection are
symptomatic, and an even smaller percentage suffers
from a mononucleosis-like syndrome w77x. When symp-
toms are present, they are usually nonspecific and mild
such as persistent low fever, muscle ache and lymph
node enlargement. The clinical course of the infection
does not seem to be affected by pregnancy. Laboratory
tests may disclose atypical lymphocytosis with a slight
rise in transaminase levels. Viral shedding occurs several
months before the infection reaches the latent phase.
Among children, viral shedding usually persists for years
after a primary infection. Toddlers in day care constitute
an important infectious source.
As occurs with other herpes viruses, CMV remains life-
long at specific sites and the viral replication cycle can
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be reactivated. Secondary infection can occur due to
such reactivation or due to infection with a different strain
(reinfection) w74, 66x. There is no licensed vaccine to pre-
vent the CMV infection in seronegative individuals. The
nature of primary maternal CMV infection makes prenatal
counseling of women complicated.
Congenital infection
Congenital CMV infection is the most prevalent infection-
related cause of congenital neurological handicap since
rubella vaccination has become universal in developed
countries w100x. CMV can cause a congenital infection
during pregnancy through the placenta, during delivery
through cervical secretions or blood and postnatally
through breast milk w12x. CMV infection via breast milk
in preterm infants is possible with different disease
patterns.
The natural history of the disease is incompletely elu-
cidated. CMV infection in pregnant women can be due
to a primary infection or a secondary infection (reinfection
or viral reactivation) w2x.
Overall, congenital CMV seems to occur in one percent
of all liveborn babies (excrete CMV in their urine), but
many international studies have methodological limita-
tions w1, 15, 35, 37, 48, 85, 90, 109x. The most reliable
birth prevalence estimates come from universal screen-
ing of all births or a representative sample of births. A
review by Kenneson in 2007 w23x found that the overall
prevalence of congenital CMV infection in all liveborn
infants in industrialized countries is likely to be 0.6–0.7%.
These results are consistent with a recent meta-analysis
with less restrictive inclusion criteria resulting in a wider
dispersion of estimates, which reported an average birth
prevalence of 0.65% w45x. This is more precise than the
range of 0.2–2.5% often cited in the literature w45, 85,
110x. There is lack of epidemiological data on the mag-
nitude of congenital CMV infection in various countries
and worldwide geographic pattern of birth prevalence
does not seem to follow a clear distribution (even within
and between countries).
Adult seroprevalence in developed countries is around
50%, but in developing countries it may be as high as
90–100%. Three French studies have shown that
43.5–51.5% of pregnant women are seronegative and
that 0.6–1.4% of the pregnant women acquire a CMV
primary infection during pregnancy w1, 15, 23, 35–37, 45,
48, 85, 90, 109, 110x. These data are similar to those
published in other developed countries w37x. The inci-
dence of secondary maternal infections remains poorly
documented w17, 71x.
Vertical transmission occurs in around 30% w101x of
infected mothers. Fetal infection does not equate to an
affected fetus. Following fetal infection, the newborn can
be symptomatic or not, and if so can develop neurolo-
gical sequelae w2x. The prognosis of symptomatic infants
is very poor, with the vast majority suffering from severe
mental impairment and/or hearing loss.
A congenital CMV infection may cause permanent
physical sequelae or impairments such as hearing loss,
visual impairment, mental retardation or milder cognitive
impairment and cerebral palsy (and also death). Damage
in the fetal brain seems to be associated with an immune
inflammatory response to CMV in the infected brain as
well as that of a direct cytopathic effect of the virus on
precursor cells of the neuroepithelium w13, 64x.
Up to 90% of symptomatic infants will have neurolog-
ical sequelae and the mortality rate can range from 2 to
30% w16, 75, 102x. Among the moderately symptomatic
neonates, 65–75% will develop normally but 25–35% will
have some degree of long-term handicap w86x.
Among asymptomatic cases at birth, between 5 and
15% cases will also develop long-term developmental
abnormalities, several months or years after birth w5, 28,
29x, mainly sensorineuro-hearing loss which can be bilat-
eral in up to 50% of cases w28, 80x. Long-term follow-up
is essential as some of the major neurological deficits
improve with time and other deficits like cognitive, learn-
ing disabilities, dyslexia, hyperactivity-inattention syn-
dromes and behavioral difficulties become apparent as
children grow older, at school age or later. The incidence
and severity of the sequelae are poorly documented, par-
ticularly their long-term outcome. They are more serious
when CMV infection is symptomatic in the neonate:
25.0% (95% CI: 3.2–65.1) to 43.7% (95% CI: 31.4–56.7)
w3, 105x when compared with 8.6% (95% CI: 0–17.8) w3x
in asymptomatic newborn infants. The characteristics of
the long-term complications after vertical transmission
following primary infection or secondary infection are not
well known, particularly in the subgroup of asymptomatic
infected newborns. Postnatal mortality due to CMV infec-
tion varies from 0 to 4.7% w70, 95x.
Risks factors for congenital infection
Factors associated with a higher prevalence of CMV con-
genital infection have been identified but are neither very
specific nor very predictive, such as young age and/or
unmarried status at the time of the first pregnancy and
low socio-economic status w36, 105x. Maternal seropre-
valence for CMV increases with maternal age and parity
w20x. Studies carried out in the United States have shown
that employees in nurseries had a higher risk of serocon-
version w69, 76x. The role of profession, however, as risk
factor for congenital CMV infection has not been proven.
Primary infection or reinfection
The rate of transmission to infants born to mothers who
had a primary infection or a recurrent infection (chronic
infection, reactivation or reinfection with a new strain)
during pregnancy was 32% and 1.4%, respectively w45x.
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Table 1 Diagnosis of an acute maternal infection.
A) IgG seroconversion (2 consecutive maternal blood samples;
the de novo appearance of virus-specific IgG in the serum of a
pregnant woman who was previously seronegative)
B) Presence of Anti-CMV IgM and igG antibodies
1) IgM may be detected in other circumstances such as:
Reactivations or reinfections
Until more than one year after CMV primary infection
Interference due to rheumatoid factor of the IgM class or
cellular antigen
False positive test if other viral infections (B19 Virus,
Epstein Barr Virus, etc)
2) Anti-CMV IgG avidity test: if inconclusive results:
Low avidity™ recent maternal infection
(threshold differs between virological methods)
The risk of severe consequences is much greater when
the pregnant women experiences a primary infection w65,
78x and also when CMV infection is acquired in the first
half of pregnancy w74x. Nevertheless, it is not universally
accepted that in utero transmission rate is higher in late
pregnancy. No data are available in immunocompromiz-
ed patients, but the baseline risk of a fetal CMV infection
may be higher.
Late congenital infections
It is difficult to study the effect of gestational age on the
outcome of congenital CMV because it is often impos-
sible to establish the time of maternal infection and no
consistent policies of prenatal screening of CMV sero-
conversion exist. According to published data, almost all
infants with symptomatic congenital infection were
exposed in the first half of pregnancy w2, 21, 57, 100x,
but few cases of congenital disease have been reported
following a third-trimester maternal infection, of which
the majority had hearing loss w21, 57, 79x. In is unclear
whether transmission rate is higher in late pregnancy w32x
but it may be as high as 58–77% in late gestation w14,
21, 32, 88x. Revello and Gerna w91x reported transmission
rates of 45.4% (49/108), 45.6% (21/46), and 78.6% (11/
14) following primary infections in the first, second and
third trimesters, respectively. In a recent study by Gindes
et al. w32x, 28 patients with late ()25 w) CMV infections
were described. Vertical transmission was proved in 75%
(21/28) of all cases when primary infection was acquired
in the third trimester. None of the 20 live infected new-
borns had symptomatic congenital infection with an
average of 33 months. In one case the patient elected to
terminate the pregnancy based on CMV DNA detection
in amniotic fluid (AF). Therefore, the severity of congenital
disease is related inversely to gestational age and is
much greater when infection occurs in the first trimester.
Secondary infection
Maternal preconceptional immunity against CMV infec-
tion gives relatively good protection to the fetus but the
frequency and the severity of fetal infection following
secondary maternal infection are poorly documented
w111x. A recent study showed that young women who
have naturally acquired preconceptional immunity to
CMV are 69% less likely to give birth to an infant with
congenital CMV infection than are those who are initially
CMV seronegative (1% vs. 3%) w30x. Assuming that
70–80% of pregnant women are seropositive prior to
conception, over 60% of the infants that were infected
in utero are born to mothers with preconceptional immu-
nity w74x. It is accepted that most infants of mothers with
preconceptional immunity have less severe neonatal
symptoms compared with those of mothers with primary
infection w11, 30x as -10% will develop postnatal
sequelae, mainly sensory neural hearing loss and chorio-
retinitis w50x. Severe congenital CMV disease and even
intrauterine fetal death have been recently reported with
secondary infection, however w17, 31, 42x. Secondary or
recurrent maternal CMV infection may be an important
cause of congenital CMV disease w4x.
A study from Israel where usually CMV screening is
performed during the first antenatal visit, reports six cas-
es with a sonographically suspected fetal infection in
mothers with a past exposure to CMV and no evidence
of recent secondary CMV infection w111x. It would seem
as maternal serology is not reliable to exclude conclu-
sively congenital CMV infection when sonographic signs
are evident.
Diagnosis
Maternal diagnosis
CMV infection occurs with a low rate of symptomatic
cases and the symptoms are often non-specific, hence
laboratory tests are needed. Diagnostic methods are
non-invasive for the mother. ELISA tests are available for
the detection of specific IgG and IgM. There is, however,
a variability among their diagnostic accuracy (sensitivity,
specificity) w87x. Different commercially available kits fre-
quently yield discordant results, limiting their diagnostic
value. Agreement between kits varies from 56% to 75%
with a sensitivity of between 30% and 88% w51x. Table
1 summarizes the diagnostic tests for maternal CMV
infection.
The presence of Anti-CMV IgM antibodies remains a
good indicator of acute or recent infection. Nevertheless
its presence can be correlated with other circumstances
than primary infection: (1) pregnant women can produce
IgM during reactivations or reinfections w52x; (2) anti-CMV
IgM antibodies can be detected in some pregnant wom-
en 6–9 months after the end of the acute phase of pri-
mary infection w100x; (3) false positive results are
common w51, 55x and may arise in patients with other
viral infections (Parvovirus B19, Epstein Barr Virus, etc).
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Table 2 Laboratory diagnosis of a fetal infection.
Amniocentesis to assess the presence of CMV in the amniotic
fluid by PCR
1) Indications:
Pregnant women with clinical signs compatible with a
primary CMV infection
Presence of ultrasound abnormalities compatible with a
fetal CMV infection
Serologic suspicion of a recent infection after a CMV
screening (despite the absence of an indication)
2) When:
G21st week of pregnancy and G5–6 weeks after estimated
onset of infection
3) Virological method:
PCR in the amniotic fluid (or viral isolation)
4) Result:
Viral DNA is detected: fetal infection is confirmed
No viral DNA detection: infection can be ruled out.
Viral load and strain polymorphism in amniotic fluid: not
indicated.
Cordocentesis for fetal infection diagnosis: not indicated.
The anti-CMV IgG avidity test seems to be the most
reliable test to identify primary infection in pregnant
women w26, 34, 52, 60x. Low avidity IgG indicates anti-
bodies caused by acute or recent primary CMV infection,
whereas high avidity indicates no current or recent pri-
mary infection w52x. Its measurement is recommended
when IgM is present w7, 25, 34, 35, 53, 54x. Anti-CMV
IgG avidity, performed before the 16th–18th week of preg-
nancy should identify all women who will have an infect-
ed fetus/newborn (sensitivity 100%) but after the 20th
week, sensitivity seems to be reduced (62.5%) w53x. If a
high avidity is found in the first 12–16 weeks of gestation,
a recent infection can be ruled out.
When comparing different assays of IgG avidity, sen-
sitivity and specificity for a recent primary CMV infection
appeared to be very high w56x. Immunoblot is the gold
standard test to confirm the presence of IgM antibodies
in serum with a high sensitivity (100%) and specificity
(100%) w56x.
Nevertheless, no reference test is currently available.
These tests are able to determine the serological status
of the pregnant woman, and to support the diagnosis of
maternal infection within the last three months with the
presence of specific IgM, associated with the compari-
son of serological results in two consecutive maternal
blood samples. The tests are technically easy to perform
but the absence of standardization and the variability of
their results according to the date of maternal infection
makes the interpretation difficult especially by non-
specialized laboratories. When an infection is suspected,
samples should be tested in a reference laboratory for
IgG avidity and to perform a specific PCR to reduce diag-
nostic errors.
Diagnosis of fetal infection
The goal is to diagnose congenital CMV infection and if
so, to detect those fetuses which are associated with
severe neurological handicap that might be eligible for an
indication to terminate pregnancy (TOP) depending on
the country’s law. Table 2 summarizes the laboratory
diagnosis of a fetal infection.
Amniocentesis A maternal CMV infection can be sus-
pected in the three scenarios detailed in Table 2.
Apart of the diagnostic value of this procedure (detec-
tion of viral genome or isolation of the virus) the AF has
been studied for prognostic evaluation. Indeed, CMV
fetal viral load in AF or CMV strain polymorphism have
been studied, but none of these two virological para-
meters seem to identify fetuses who will be symptomatic
at birth. The results of the studies are contradictory w8,
33, 59, 81–83x.
To diagnose fetal infection, an amniocentesis should
then be performed to assess the presence of CMV in AF
by PCR (polymerase chain reaction) (sensitivity and
specificity, 90–98% and 92–98%, respectively) with
respect to viral transmission from mother to fetus w27,
38, 58, 88, 94x. Viral isolation of the CMV virus from the
AF is indicative of congenital infection too, but this pro-
cedure requires the long viral cultivation on fibroblasts
and is less sensitive (70–80%).
AF is the most appropriate material w24, 27, 38, 58, 88x
and obviates the need for cordocentesis w108x. CMV
could potentially be transmitted by antenatal diagnostic
procedures by DNA in maternal blood but the risk seems
to be small w56, 92x. AF should be sampled after the 21st
week of gestation and at least 5–6 weeks after the esti-
mated onset of infection, for several reasons: (1) the virus
is only eliminated in fetal urine in sufficient amounts after
6–9 weeks of maternal infection w94x, and (2) the risk of
a severe fetal infection is higher if contracted early in
pregnancy w79x, (3) false negative results are common if
the amniocentesis is performed earlier. The negative pre-
dictive value for fetal infection is almost 100%. A good
performance of diagnostic and confirmatory tests as well
as correct interpretation and communication of these
results to pregnant women may significantly reduce the
rate of unnecessary terminations of pregnancy w39x.
Fetal blood Fetal blood sampling (FBS) by cordocen-
tesis involves a risk of miscarriage of 0.5–1% and does
not give any additional diagnostic value and carries a
high risk of fetal demise and therefore, should not be
performed. A recent report by Benoist et al. w10x sug-
gests that despite the high procedure related loss rate,
FBS should be performed for fetal platelet count deter-
mination in fetuses with known CMV infection because
of its own independent prognostic value for a bad out-
come (including disseminated infection when termination
of pregnancy (TOP) have been performed or sympto-
matic disease in newborns). This should, therefore, be
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Table 3 Imaging and CMV congenital infection.
A) Screening of fetal infectionsdiagnostic value
Ultrasound features related to CMV infection are
numerous and non-specific
If structural and/or growth abnormalities are observed,
CMV infection can be suspected: maternal serologies
should be obtained (if IgG negative, CMV infection can
be ruled out) (if igG is positive, amniocentesis for CMV
genome detectioncan be proposed)
B) Prediction of an adverse outcome among infected fetusess
prognostic value
Infected fetus with ultrasound abnormalities is at risk to
be symptomatic at birth
Fetal brain abnormalities are associated with a high risk
for the newborn to be symptomatic
Ultrasound or MRI are the most powerful tools to predict
an adverse outcome
Unfortunately, brain examinations are more efficient when
performed later in gestation (especially MRI).
considered as part of the prognostic evaluation but not
for diagnostic purposes.
Ultrasound The goal of prenatal assessment of CMV
congenital infection is to identify fetuses that will be
symptomatic at birth and will have an abnormal psycho-
motor development. The most powerful tools to predict
an adverse outcome are ultrasound or MRI assessments
of fetal anatomy. Ultrasound is a non-invasive technique
that discloses structural and/or growth abnormalities
caused by CMV infection. Nevertheless, it only identifies
around 25% of infected babies w107x. Recently, Guerra
et al. w40x have shown that the positive predictive value
of ultrasound for symptomatic CMV infection was low
(35.29%) for all fetuses exposed in utero (maternal infec-
tion), and increased (78.26%) for congenitally infected
fetuses (proved by the positive AF).
Fetal ultrasound features related to CMV infection are
numerous and non-specific. Among these, an abnormal
feature in the fetal brain on ultrasound is likely to be pre-
dictive of neurologically symptomatic neonates w10, 62,
103x.
If a congenital infection is diagnosed, all patients
should be screened for brain anomalies such as ventri-
culomegaly, criteria for visceral disease such as fetal
growth restriction, hepato-splenomegaly w97, 98x, hyper-
echogenic bowel, liver calcifications, and ascites. Unfor-
tunately, lesions (especially cerebral) may evolve during
pregnancy and may be seen when TOP is no longer
possible in certain countries. Cortical developmental
disorders will not be seen before 26 weeks, therefore,
examinations performed later in gestation might be more
diagnostic. Recently, La Torre et al. w49x compared the
placental thickness (measured between 16 and 36 weeks
of gestation) of 92 women with primary CMV infection
during pregnancy and 73 CMV-seropositive pregnant
women without primary CMV infection. They reported
that primary maternal CMV infection and fetal or neonatal
disease are associated with sonographically thickened
placentas. More studies are required to confirm this
finding.
Magnetic resonance imaging Some studies have
shown that MRI may provide additional information in
the infected fetus, especially to assess the fetal brain of
those with a normal ultrasound, and especially when
ultrafast sequences can be performed. Picone et al. w84x
reported 46% of brain abnormal findings in 13 infants
with a normal ultrasound assessment and in all 14 cases
with abnormal brain by ultrasound. Nevertheless, MRI
might be misleading before 26 weeks. The number of
cases in this study was too small and all cases were
evaluated between 24 and 37 weeks’ gestation. Despite
promising results, no final conclusions can be drawn
regarding the use of MRI in CMV-infected fetuses (Table
3). In the high-risk group of proven infected fetuses, MRI
could provide a theoretically better assessment of the
development of the white matter and the cerebral cortex
than does ultrasound because of the poor performance
of ultrasound alone w40, 41x. The optimal gestational age
to perform MRI is probably around 32–34 weeks.
Neonatal diagnosis and follow-up
A congenitally acquired CMV infection should always be
confirmed at birth.
Clinical diagnosis Table 4 describes the outcome of
neonates and infants who congenitally acquire CMV
infection in utero. Around 10% of infected newborns will
be symptomatic at birth w28x and the risk of severe
sequelae is greater among this group of infants.
Ninety percent of congenitally infected newborns are
asymptomatic. About 15% of these infants have pro-
gressive hearing loss that is usually unilateral. In addition,
some have suggested cognitive sequelae in these
children w18x.
Infants who are symptomatic (10%) are usually small
for gestational age and have hepatomegaly, splenomeg-
aly, thrombocytopenia (petechiae, purpura), jaundice,
microcephaly, seizures, abnormal neurologic examina-
tion, and feeding problems w55x. Their incidence will vary
depending on the time of examination. Brain abnormali-
ties found on CT scan include periventricular cysts and
calcifications, ventriculomegaly, vasculitis, hydranence-
phaly, and neuronal migration abnormalities w34x. Ocular
abnormalities include chorioretinitis, retinal scars, optic
atrophy, and central vision loss w26x. Sensorineural hear-
ing loss occurs in almost 70% of congenitally infected
infants and this condition is almost always progressive.
Less commonly, endocrinopathies such as diabetes
mellitus or Graves disease have been observed. The
presence of microcephaly, intracranial calcifications, or
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Table 4 Newborns with a prenatal CMV infection.
A) Residual prenatal infection
Microcefalia, periventricular calcifications
Poor prognosis, cerebral palsy (90%), cognitive
impairment, visual impairment
Perinatal mortality 2–30%
B) Active infection
Sepsis like, thrombocytopenia
Sensorial hearing loss, cognitive impairment,
visual impairment (25–35%)
C) Asymptomatic
Sensorial hearing loss 5–15%
Table 5 Postnatal diagnosis and follow-up.
Congenitally infection should be confirmed at birth within
three weeks
Test: Urine culture or CMV-DNA testing by PCR
If infection is confirmed: classify according to the presence or
absence of clinical and laboratory abnormalities as sympto-
matic or asymptomatic
Follow-up: 1, 3, 6 and 12 months of life and annually until
school age to (detection of sequela with delayed onset).
Monitoring:
Physical, neurological and anthropometric evaluation:
Neurodevelopmental evaluation, auditory brainstem
responses; fundus oculi;
Laboratory tests:
Complete blood count, platelet count, transaminase
level, bilirubin levels (direct and indirect)
Urine sampling for virus isolation.
If a symptomatic infection diagnosed later in the neonatal period:
CMV-PCR can be performed on blood adsorbed on Guthrie
cards, collected at birth can be used to reassess fetal status at
birth.
other CT abnormalities with chorioretinitis predicts poor
neurodevelopmental outcome w18x.
Perinatal infection is usually asympmtomatic and usu-
ally occurs from three weeks to six months of age but
may cause a septic syndrome (hepatomegaly, spleno-
megaly, lymphocytopenia, neutropenia, thrombocytope-
nia, elevated liver aminotransferases, and pneumonia).
These symptoms appear to be transient and have no
effect on neonatal outcome (growth, necrotizing entero-
colitis, bronchopulmonary dysplasia) w60x.
Laboratory findings Laboratory findings include ele-
vated aminotransferases, direct and indirect serum bili-
rubin, thrombocytopenia, and hemolytic anemia w55x.
Detection of CMV IgG in the neonate is not very helpful
in making a diagnosis of congenital infection due to pas-
sive transfer of antibody across the placenta. CMV IgM
detection in the newborn suggests congenital infection,
but usually needs to be confirmed with viral culture w18x
or viral PCR in urine. The presence of specific IgM in
neonatal serum also confirms a congenital infection, but
is only present in 70% of infected babies w89x.
The reference method for diagnosing congenital CMV
infection involves isolating the virus in cell culture from
urine collected within three weeks of birth (urine culture
or CMV-DNA testing by PCR) (Table 5). After three weeks,
a positive CMV result in urine might well be the conse-
quence of exposure to infected vaginal secretions at
delivery, or through breast feeding, or untested transfu-
sions w22x. If virus is isolated from the urine, the infected
babies should be monitored. If viral isolation is negative,
the baby is considered uninfected and no further tests
are required. Infected neonates should be evaluated at
1, 3, 6 and 12 months of age and thereafter annually until
school age. Monitoring includes physical, neurological
and anthropometric evaluation; neurodevelopmental
evaluation; auditory brainstem responses; ophthalmolog-
ic examination; blood sampling for laboratory tests (com-
plete blood count, platelet count, transaminase level,
direct and indirect bilirubin levels); and urine sampling for
virus isolation. CMV-infected offspring should undergo an
extended follow-up to identify sequelae with delayed
onset.
CMV genome detection using PCR on blood adsorbed
on Guthrie cards (dried blood spot), collected at birth for
neonatal screening for metabolic and hereditary diseases
seems to be a sensitive and specific test for late diag-
nosis of congenital CMV infection w99x. Vauloup-Fellous
et al. w106x reported high sensitivities and specificities of
real-time PCR on dried blood spots; respectively,
94.7–100% and 97.3–94.7% in relation with the virolog-
ical method used. Nevertheless, the authors observed a
lesser detection threshold for real time PCR in blood
spots than in urine samples. It can be of great value when
there is a strong clinical suspicion of congenital CMV
infection w9x. Tests for viral DNA using neonatal blood
dried on paper could be used to better understand and
monitor the true burden of congenital CMV but also to
identify delayed onset sequelae such as sensorineural
deafness, abnormalities of cortical development, neo-
natal cholestasis w9x.
Management options
Currently, no therapeutic options are available except for
clinical trials. Several promising options have been
described.
Hyperimmune globulin
In the pregnant woman with primary CMV infection, the
use of CMV-specific immune globulin, though still inves-
tigational, is gathering attention and may prove to be a
valuable therapy w96x. To date, preliminary results on
treatment of CMV congenital infection during pregnancy
are available from two studies. Nigro et al. w72x published
the retrospective results of a non-randomized clinical trial
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using intravenous CMV hyperimmune globulin (HIG) for
CMV maternal primary infection. In a first group of 45
infected women with a CMV positive amniocentesis
(treatment group), 31 were given 1–3 infusions of 200 UI
of HIG while 14 elected not to have the treatment. In the
31 treated women, only one delivered an infant with CMV
disease whereas 7 of 14 non-treated women delivered
severely symptomatic infants with neurological involve-
ment. In a second group (‘‘preventive group’’), 37 women
with primary infection received 100 U of HIG monthly
until delivery and 65 did not. The main outcome criterion
in this second group was the proportion of infected new-
borns. Sixteen percent of the treated women compared
to 40% of untreated women delivered an infected baby
(Ps0.02). Considering this protocol and results, several
remarks can be made. In the first part of the study, the
rate of severe infection with neurological involvement in
the infants of the 14 non-treated women (50%) was sur-
prisingly high compared to the 10% of severe infection
usually reported in the literature. Even more surprising,
14 infected fetuses with ultrasound abnormalities
including ventriculomegaly, ascites, hepatosplenomega-
ly, intrauterine growth retardation, liver and bowel hyper-
echogenicity and periventricular echodensities, seemed
to have completely recovered following HIG administra-
tion. In the second part of the study, vertical transmission
was 16% and 40% with and without treatment,
respectively.
A more recent publication by the same group reported
the regression of fetal cerebral abnormalities by primary
CMV infection following hyperimmunoglobulin therapy in
three patients. Their sensorial, mental and motor devel-
opment at follow-up was normal at 4, 4.7, and 7 years
of age. In contrast, the two infants born of untreated
mothers had signs and symptoms of severe CMV cere-
bropathy w73x.
Moxley et al. w67x also reported a case of fetal hydrops
that resolved after maternal and fetal intravenous admin-
istration of CMV HIG. These results have to be interpret-
ed with caution and highlight the necessity of evaluating
further this therapeutic option. Although antiviral drugs
are commonly used for prophylaxis of CMV disease in
recipients of solid organ transplants, currently there are
no indications for IgG as prophylaxis for CMV disease in
recipients of solid organ transplants w43x.
Antiviral treatments
Treatment options for fetal CMV are limited. A number of
antiviral drugs are active against CMV. Three of them
(ganciclovir, cidofovir and foscarnet) are licensed to treat
immunocompromised patients. Nevertheless, all these
drugs have common limitations that are clinically relevant
such as toxicities, drug-drug interactions, poor bioavail-
ability and the development of drug resistance. Currently,
potential teratogenic effects and well known toxicity of
available drugs do not support their use in pregnancy.
The development of new anti-CMV compounds to treat
the infected immunocompromised patient are currently at
different stages of trial, several of these compounds are
very promising in term of efficacy and toxicity. It will be
long before they can be tested for treatment of congenital
CMV infection.
Aciclovir (ACV) and its pro-drug Valaciclovir (VACV) are
active against CMV. Even if its use in pregnant women is
not licensed, ACV was given for more than 20 years to
pregnant women for herpes simplex infection without any
significant reported side effects. Jacquemard et al. w44x,
recently reported the results of a prospective pilot trial of
oral VACV in fetuses infected by CMV. Twenty pregnan-
cies including 21 fetuses were treated at 28 weeks (medi-
an, range: 22–34) for 7 weeks (median, range: 1–12).
Pregnancies with confirmed fetal CMV infection (positive
PCR in AF) were treated with oral VACV (8 g/day). Data
were compared with an untreated group of 24 infected
fetuses. In both groups, the outcome was recorded. To
establish the pharmacokinetic features of the drug, fetal
viral load and drug concentrations were monitored in AF
and in fetal blood (FB) as well as therapeutic concentra-
tions in maternal and FB. AF and FB sampling were per-
formed at 26 weeks (SD"3 weeks) and controlled at
32 weeks (SD"3 weeks). The viral load in FB decreased
significantly after 1–12 weeks of treatment (Ps0.02).
Among the 21 fetuses in the treated group, 10 are devel-
oping normally at between one and five years of age. Two
infants (both 2 years) had severe isolated unilateral deaf-
ness. One neonate presented with microcephaly and
severe deafness but was also diagnosed with inconti-
nentia pigmenti. Six out of seven cases that eventually
requested TOP had evidence of in utero progression of
the disease with worsening cerebral lesions. One fetus
died in utero. Overall, the outcome was unfavorable in
11/21 (52.4%) treated fetuses vs. 14/24 (58.3%) in
untreated fetuses, who had either TOP, intrauterine fetal
demise (IUFD) or severe congenital infection; the remain-
ing 10 infants remained healthy at follow-up. These pre-
liminary results suggest that VACV could be considered
in cases where TOP is declined, and perhaps indicated
for infected fetuses without abnormalities at cerebral
imaging. A randomized controlled trial to study this treat-
ment option has recently been accepted by the French
public health authorities and is being conducted.
Table 6 summarizes in utero treatment options for
infected fetuses. Globally, several potential interventions
have been proposed for congenital CMV, such as
hygiene education to prevent primary infection among
pregnant women w19x, prenatal maternal screening to
identify candidates for HIG w72x or antiviral therapies w61x,
and newborn screening for early diagnosis of delayed
hearing loss w29x or treatment with antiviral therapy w46x.
These public health interventions, however, are seldom
implemented due to concerns about safety, effective-
ness, or cost-effectiveness, and due to lack of awareness
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Table 6 In utero treatment options for infected fetuses.
If a fetal infection is confirmed: careful risk assessment of the
risk of long of permanent sequela and different options should
be discussed
Abnormalities on ultrasound or MRI
No present™low risk of sequela. TOP not indicated
Present™TOP should be offered if in accordance with local
laws
If TOP can only be performed until the 22–24 week: inform
patient on the risk of long-term sequela despite the
absence of abnormal imaging
Antivirals and intravenous CMV hyperimmune globulin: very
promising but results have to be interpreted with caution.
Currently their use not is not recommended outside
randomized controlled trials.
about the magnitude of the burden of congenital CMV
disease.
Termination of pregnancy
When a fetal symptomatic infection is diagnosed and
confirmed, the patient should be carefully assessed for
the risk of long permanent sequela and different man-
agement options should be discussed. If local laws
permit, TOP might be offered. When local laws only
authorize TOP up to the 22–24 weeks, the patient should
be informed on the risk of long-term sequelae despite
the absence of abnormal imaging.
Neonatal treatment
The newborn infant can be treated when prenatal CMV
infection is recognized. Newborn infant, preterm or term,
can be treated when there is an active clinical infection
(sepsis like) and, especially, persistent thrombocytope-
nia. Treatment of acquired asymptomatic congenital or
perinatal acquired CMV infection in the newborn is not
currently recommended. Treatment of those with symp-
tomatic infection remains controversial, but may be of
benefit in the short-term (viral sepsis-like syndrome
caused by CMV, pneumonia, severe refractory thrombo-
cytopenia) w25x, and long-term (sensorial hearing loss,
microcephaly) w7, 54x. The most effective option for the
treatment of life- or sight-threatening CMV disease at any
age is the nucleoside-analog ganciclovir. For the new-
born with congenital CMV infection, the value of ganci-
clovir appears to preserve hearing; other improvements
in overall neurodevelopmental status are inferred but
remain to be proven w98x. Although doses of ganciclovir
have ranged from 6 to 12 mg/kg/dose, 6 mg/kg per dose
every 12 h intravenously for six weeks appears to be
effective w53x. Intravenous ganciclovir administered for
six weeks improves hearing outcomes in infants with
symptomatic congenital cytomegalovirus (CMV) disease
involving the central nervous system. The median dose
of oral valganciclovir is 16 mg/kg. Neutropenia developed
in 38% of subjects. Valganciclovir oral solution provides
plasma concentrations of ganciclovir comparable to
those achieved with administration of intravenous gan-
ciclovir w47, 68x.
Prevention
Prevention is difficult because the virus is ubiquitous and
infection is common. Development of a CMV vaccine is
one of the highest health priorities, but availability of a
licensed vaccine to prevent CMV infection in seronega-
tive individuals is not imminent w6x.
Primary infection
The nature of primary maternal CMV infection compli-
cates prenatal counseling. Pregnant women at risk of
acquiring CMV may be counseled on how CMV may be
transmitted and on hygienic measures that could be
implemented. Although very controversial, there are
some practices that might minimize the risk for congen-
ital infection. Seronegative women of childbearing age
should be aware of prevention measures including w4, 53,
56x: 1) good hand washing with soap and water after
contact with diapers or oral secretions, 2) evaluate wom-
en for CMV who develop a mononucleosis-like illness
during pregnancy, 3) female are taking cares who of
infants or children should be educated concerning CMV,
4) susceptible non-pregnant women working with infants
or children should not routinely be transferred to other
work situations, 5) pregnant women working with infants
and children should be informed of the risk of acquiring
CMV, 6) routine laboratory testing for CMV antibody in
female workers is not recommended but can be per-
formed to determine immune status.
The prevention behaviors (i.e., hand washing, not shar-
ing drinking glasses or eating utensils with young chil-
dren, and not kissing young children on the mouth)
appear to be generally acceptable. These are prevention
behaviors that have the potential to substantially reduce
CMV-related permanent disability in children. However,
results suggest that few women are aware of CMV or of
these prevention behaviors w93x.
CMV can also be transmitted by sexual intercourse but
the role of seropositive or seroconverting partners has
also to be elucidated w63x.
Should pregnant women be screened for CMV?
Before implementing a screening program for CMV dur-
ing pregnancy, its feasibility, acceptability by the target
population and benefit-risk should be assessed. The aim
of antenatal screening would be to decrease the inci-
dence of the serious complications caused by congenital
CMV infection in infected infants. Systematic screening
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of the pregnant women could lead to: (I) anxiety, (II) an
increased number of amniocentesis and therefore of mis-
carriages, (III) an unjustified number of termination of
pregnancies (TOP) that would be performed even in the
absence of a bad prognosis such as ultrasound markers.
TOP may be restricted in some countries after certain
weeks of pregnancy and such policy may be difficult to
undertake.
Updated estimates of the impact of congenital CMV
are needed for increased awareness of the true burden
of congenital CMV infection and disease, allocation of
public health resources, and determination of the cost-
effectiveness or cost-benefit of potential interventions
w45x. No evaluation of the cost of a systematic CMV
screening policy is available. The absence of a consen-
sual algorithm in the management of these cases makes
any estimate even more difficult.
Currently, no country performs systematic screening
for CMV infection among pregnant women as universal
screening for CMV primary infection is not recommend-
ed. Nevertheless in certain areas, largely uncontrolled
serologic screening is increasingly performed with the
objective of prenatal diagnosis. However, the appropri-
ateness of screening for CMV infection in pregnant
women is controversial. Most primary infections are
asymptomatic (up to 90%), it is difficult to establish fetal/
neonatal prognosis and there are no well established pre-
ventive measures as well as curative treatment of fetal
infection.
Things to avoid include: 1) recovery of CMV from the
cervix or urine of women at or before delivery does not
require a cesarean section, 2) the benefits of breastfeed-
ing far outweigh the minimal risk of acquiring CMV from
breastfeeding mother, and 3) although preliminary data
suggest the potential benefit of IVIG to prevent congen-
ital CMV infection, the study was not randomized or con-
trolled and did not evaluate the financial, logistic, and
clinical (false positive) problems associated with screen-
ing of a large obstetrical population.
Perinatal infection
Preterm infants below 1000 g and 30 weeks may be at
high risk of acquiring a symptomatic CMV infection.
There are some practices that may minimize this risk for
perinatal infection. Most nurseries provide CMV serone-
gative or leukocyte reduced blood products to newborns.
No evidence has yet been found in preterm neonates for
sequelae related to CMV infection acquired via breast
milk. The administration of fresh breast milk to very pre-
mature neonates who constitute a population at risk is
controversial w104x. Pasteurization and freezing breast
milk at y208 may reduce or eliminate the viral load and
the transmission of CMV in human milk, although it may
also reduce some of its benefits w104x.
Conclusions and perspectives
Congenital CMV infection is the most prevalent infection-
related cause of congenital neurological handicap. Over-
all, prevalence of congenital CMV infection in all liveborn
infants in industrialized countries is likely to be 0.6–0.7%.
Vertical transmission occurs in around 30% but the fetus
is not always affected. If the newborn is symptomatic at
birth, prognosis is poorer and a high risk of severe neu-
rological sequelae exists. The majority of severe cases
develop after a maternal primary infection during the first
half of pregnancy. Nevertheless, late congenital infec-
tions and even secondary infections may cause perma-
nent sequelae but are much less severe. A maternal
infection is confirmed if an IgG seroconversion is docu-
mented in two consecutive blood samples. Anti-CMV
IgG avidity test may add some benefit if results are
inconclusive.
If a seroconversion is documented or a fetal infection
is suspected by ultrasound markers, women should
undergo an amniocentesis to evaluate if a congenital
infection has occurred. The test should be performed at
least after 21–22 weeks of pregnancy and a positive test
is associated with a likely primary infection that occurred
at least six weeks earlier. A congenitally acquired CMV
infection should be confirmed at birth (presence of CMV
in urine).
Diagnosis and management of fetal infection is com-
plex and should be performed by a multidisciplinary team
or in a specialized Unit of Fetal Medicine. Currently, this
diagnosis involves primarily the assessment of fetal prog-
nosis and the question of termination of an infected/
affected fetus. In the absence of a confirmed fetal
infection, a pregnancy termination should then be
discouraged.
If a congenital infection is confirmed, fetal prognosis is
difficult to establish. Serial ultrasound examinations
should be performed to assess mainly the presence of
brain damage.
Current treatment options for fetal CMV are very lim-
ited. Despite promising results with antiviral drugs and
CMV HIG, they have to be interpreted with caution. The
potential teratogenic effect and toxicity of the current
available drugs do not support their use in pregnancy.
Pregnant women should not be systematically tested
for CMV during pregnancy. Managing CMV screening
should be restricted to pregnancies where a primary
infection is suspected (maternal clinical signs or fetal
ultrasound markers) or among women at high risk (day
care centers, immunocompromised patients: HIV, solid
organ transplant, etc.),
The real magnitude of the burden of congenital CMV
disease and the value of interventions to prevent con-
genitally acquired CMV or to decrease the sequelae
should be established before implementing public health
interventions.
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